Example: Heart Attack

Search clinical trials for: Maytansine

Total 107 results

NCT04189211

Active, not recruiting

A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients

Conditions: HER2-Positive Solid Tumors
NCT04606914

Not yet recruiting

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube; Primary Peritoneal Cancer
NCT04296890

Recruiting

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

Conditions: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
NCT03832361

Recruiting

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Conditions: Endometrial Cancer
NCT03106077

Completed

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Conditions: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Negative; Folate Receptor Alpha Positive; HER2/Neu Negative; Progesterone Receptor Negative; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Triple-Negative Breast Carcinoma
NCT03045393

Withdrawn

Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

Conditions: Breast Cancer Triple Negative
NCT03023722

Completed

Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

Conditions: Pancreatic Cancer
NCT02839681

Terminated

Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

Conditions: Lung Neoplasms
NCT02696642

Completed

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Conditions: Neoplasms
NCT01638936

Completed

BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma

Conditions: Multiple Myeloma
NCT01609556

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

Conditions: Tumors
NCT01001442

Completed

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma
NCT01470456

Completed

Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Conditions: Diffuse Large B-Cell Lymphoma
NCT01440179

Terminated

SAR3419 in Acute Lymphoblastic Leukemia

Conditions: Acute Lymphocytic Leukaemia
NCT01472887

Completed

SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

Conditions: Diffuse Large B-cell Lymphoma
NCT03926143

Enrolling by invitation

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Conditions: Cancer
NCT02420873

Completed

An Open-label Phase II Study of Lorvotuzumab Mertansine

Conditions: Leukemia
NCT02254044

Terminated

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

Conditions: Carcinoma, Squamous Cell
NCT02254031

Terminated

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

Conditions: Breast Neoplasms
NCT02254018

Completed

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Conditions: Head and Neck Neoplasms
NCT02254005

Completed

Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer

Conditions: Breast Neoplasms
NCT03836157

Withdrawn

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Conditions: Endometrial Cancer; Endometrial Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Clear Cell Adenocarcinoma
NCT03552471

Recruiting

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions: BRCA1 Gene Mutation; BRCA2 Gene Mutation; Folate Receptor Alpha Positive; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Recurrent Uterine Serous Carcinoma; Recurrent Uterine Carcinosarcoma; Platinum Resistant Ovarian Cancer
NCT03126630

Recruiting

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Conditions: Pleural Malignant Mesothelioma
NCT02996825

Recruiting

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Conditions: Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Triple-Negative Breast Carcinoma